Abstract
Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 509-512 |
| Number of pages | 4 |
| Journal | Pediatric Blood and Cancer |
| Volume | 53 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2009 |
Fingerprint
Keywords
- Aplidin
- Developmental therapeutics
- Pre-clinical testing
ASJC Scopus subject areas
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology
Cite this
Initial testing of Aplidin by the pediatric pre-clinical testing program. / Morton, Christopher L.; Houghton, Peter J.; Gorlick, Richard; Kolb, E. Anders; Lock, Richard; Carol, Hernan; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Billups, Catherine; Smith, Malcolm A.
In: Pediatric Blood and Cancer, Vol. 53, No. 3, 09.2009, p. 509-512.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Initial testing of Aplidin by the pediatric pre-clinical testing program
AU - Morton, Christopher L.
AU - Houghton, Peter J.
AU - Gorlick, Richard
AU - Kolb, E. Anders
AU - Lock, Richard
AU - Carol, Hernan
AU - Keir, Stephen T.
AU - Reynolds, C. Patrick
AU - Kang, Min H.
AU - Maris, John M.
AU - Billups, Catherine
AU - Smith, Malcolm A.
PY - 2009/9
Y1 - 2009/9
N2 - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.
AB - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.
KW - Aplidin
KW - Developmental therapeutics
KW - Pre-clinical testing
UR - http://www.scopus.com/inward/record.url?scp=67651204923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651204923&partnerID=8YFLogxK
U2 - 10.1002/pbc.21976
DO - 10.1002/pbc.21976
M3 - Article
C2 - 19418543
AN - SCOPUS:67651204923
VL - 53
SP - 509
EP - 512
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 3
ER -